HI HB2456

Requires the Hawaii Department of Human Services to provide Medicaid coverage for FDA-approved GLP-1 weight loss drugs, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), which are currently excluded from coverage for most Medicaid recipients.

Patients must participate in a lifestyle change program supporting long-term weight loss maintenance to qualify for coverage, and the drug must be prescribed by a practitioner.

Prohibits prior authorization requirements for covered GLP-1 weight loss medications.

Department of Human Services must issue temporary rules by August 1, 2026, and adopt permanent rules by January 1, 2028.

Appropriates an unspecified amount from general revenues for fiscal year 2026-2027 to fund the Medicaid coverage expansion, with the Act taking effect July 1, 2026.